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Differential diagnosis of parkinsonism: a head-to-head
comparison of FDG PET and MIBG scintigraphy
Joachim Brumberg 1,8✉, Nils Schröter 2,3,8, Ganna Blazhenets4, Lars Frings 4, Jens Volkmann5, Constantin Lapa 1,6,
Wolfgang H. Jost7, Ioannis U. Isaias 5 and Philipp T. Meyer4
[18F]fluorodeoxyglucose (FDG) PET and [123I]metaiodobenzylguanidine (MIBG) scintigraphy may contribute to the differential
diagnosis of neurodegenerative parkinsonism. To identify the superior method, we retrospectively evaluated 54 patients with
suspected neurodegenerative parkinsonism, who were referred for FDG PET and MIBG scintigraphy. Two investigators visually
assessed FDG PET scans using an ordinal 6-step score for disease-specific patterns of Lewy body diseases (LBD) or atypical
parkinsonism (APS) and assigned the latter to the subgroups multiple system atrophy (MSA), progressive supranuclear palsy (PSP),
or corticobasal syndrome. Regions-of-interest analysis on anterior planar MIBG images served to calculate the heart-to-mediastinum
ratio. Movement disorder specialists blinded to imaging results established clinical follow-up diagnosis by means of guideline-
derived case vignettes. Clinical follow-up (1.7 ± 2.3 years) revealed the following diagnoses: n= 19 LBD (n= 17 Parkinson’s disease
[PD], n= 1 PD dementia, and n= 1 dementia with Lewy bodies), n= 31 APS (n= 28 MSA, n= 3 PSP), n= 3 non-neurodegenerative
parkinsonism; n= 1 patient could not be diagnosed and was excluded. Receiver operating characteristic analyses for discriminating
LBD vs. non-LBD revealed a larger area under the curve for FDG PET than for MIBG scintigraphy at statistical trend level for
consensus rating (0.82 vs. 0.69, p= 0.06; significant for investigator #1: 0.83 vs. 0.69, p= 0.04). The analysis of PD vs. MSA showed a
similar difference (0.82 vs. 0.69, p= 0.11; rater #1: 0.83 vs. 0.69, p= 0.07). Albeit the notable differences in diagnostic performance
did not attain statistical significance, the authors consider this finding clinically relevant and suggest that FDG PET, which also
allows for subgrouping of APS, should be preferred.
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INTRODUCTION
Radionuclide or molecular imaging techniques support the differ-
ential diagnosis of parkinsonism1,2 and have been incorporated into
current international diagnostic criteria3–6. The recommendations
refer to both [18F]fluorodeoxyglucose (FDG) PET as well as [123I]
metaiodobenzylguanidine (MIBG) scintigraphy for the differential
diagnosis in uncertain clinical cases of suspected neurodegenerative
parkinsonism. The selection of a specific technique relies on the
particular clinical presentation and question (see guidelines, e.g.
pathological MIBG scintigraphy as supportive criterion for Parkinson’s
disease [PD] or degeneration of putamen on FDG PET as a feature of
possible multiple system atrophy [MSA]).
FDG PET is used to image regional cerebral glucose metabolism
as a marker of neuronal activity that may be altered through
neurodegeneration and disease-specific network changes. The
identification of cerebral metabolic patterns related to specific
neurodegenerative diseases7 allows to separate Lewy body
diseases (LBD; i.e. PD, PD dementia [PDD], and dementia with
Lewy bodies [DLB]) from atypical parkinsonian syndromes (APS)
with high diagnostic accuracy8,9. Alternatively, the involvement of
the autonomous nervous system can be assessed by imaging
postganglionic cardiac innervation with MIBG and planar scinti-
graphy. Cardiac MIBG uptake is markedly reduced in patients with
LBD when compared to healthy controls and APS10. Unlike with
FDG PET, a further differentiation between the APS subgroups
MSA, progressive supranuclear palsy (PSP), and corticobasal
syndrome (CBS) is not possible with MIBG scintigraphy. However,
the preferred method is unclear and a direct comparison of both
methods is still lacking.
Against this background, the present multicenter study compares
the performance of FDG PET and myocardial MIBG scintigraphy in
the differential diagnosis of neurodegenerative parkinsonism in the
same patient population. Although reduced myocardial innervation
is a common finding in LBD in contrast to preserved innervation in
non-LBD, most available data on MIBG scintigraphy addresses the
differentiation between PD and MSA. Thus, the present study
addresses both aforementioned distinctions.
RESULTS
Patient characteristics
Clinical consensus rating revealed a final follow-up diagnosis of
LBD in 19 patients (PD, n= 17; PDD, n= 1, DLB, n= 1), and a
diagnosis of APS in 31 patients (MSA, n= 28; PSP, n= 3). Three
patients had another diagnosis than neurodegenerative parkin-
sonism (i.e. drug-induced parkinsonism, n= 2, normal pressure
hydrocephalus, n= 1). In one patient the lack of sufficient clinical
data precluded a final diagnosis. This subject was excluded from
statistical analyses, whereas no patient had to be excluded
because of interfering medication or corrupted imaging data. All
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patients who underwent dopamine transporter SPECT during the
time course of clinical observation showed a pathological scan
result, confirming neurodegeneration (clinical diagnosis of LBD in
n= 12 and non-LBD in n= 11). There were no group differences in
terms of sex, age at first imaging, and time of clinical observation
between patients with LBD and non-LBD as well as between
patients with PD and MSA. However, not unexpectedly, symptom
duration at first imaging was longer in patients with LBD (vs. non-
LBD; p= 0.001) and PD (vs. MSA; p < 0.001), respectively (Table 1).
Discriminative analysis of FDG PET and MIBG scintigraphy
Inter-rater agreement was very high to excellent (FDG score:
weighted κ= 0.85 [95%-confidence interval (CI): 0.85–0.85]; FDG
second-level diagnosis: κ= 0.80 [0.65–0.94]; MIBG H/M: ICC r=
0.99 [0.98–0.99]). FDG PET separated non-LBD from LBD and MSA
from PD with a ROC AUC of 0.82 (0.68–0.97) and 0.82 (0.67–0.98),
respectively, and with large effect sizes (LBD vs. non-LBD: d= 1.6;
PD vs. MSA: d= 1.7; Figs. 1a, c and 2). For MIBG scintigraphy, the
ROC AUC for differentiation between LBD and non-LBD and
between PD and MSA were notably smaller (0.69 [0.53–0.85] and
0.69 [0.52–0.86], respectively; Fig. 2), yielding medium to large
effect sizes (LBD vs. non-LBD: d= 0.7; PD vs. MSA d= 0.7; Figs. 1b,
d). For differentiating LBD vs. non-LBD, the difference between the
ROC AUC for FDG PET and MIBG showed a tendency towards
statistical significance (p= 0.06; Fig. 2a). The difference between
the ROC AUC was comparable for the differentiation of PD vs.
MSA, but missed trend level significance in the smaller patient
sample (p= 0.11; Fig. 2b). Interestingly, the ROC AUC for FDG PET
was significantly greater than that for MIBG scintigraphy for
differentiation of LBD vs. non-LBD for rater #1, who has more
experience in FDG PET readings (0.83 [0.69–0.96] vs. 0.69, p= 0.04;
trend level for PD vs. MSA: 0.83 [0.68–0.98] vs. 0.69 p= 0.07).
Further sub-analyses after the exclusion of three patients with
non-neurodegenerative parkinsonism (i.e. LBD vs. APS) and two
additional patients clinically rated as PDD/DLB (i.e. PD vs. APS)
confirmed overall findings without substantial changes of the ROC
AUC of FDG PET (LBD vs. APS: 0.84 [0.70–0.98]; PD vs. APS: 0.82
[0.67–0.98]) and MIBG scintigraphy (LBD vs. APS: 0.71 [0.55–0.87];
PD vs APS: 0.68 [0.51–0.85]; FDG PET vs. MIBG scintigraphy, each
p= 0.08; for more details see Supplementary Table 1).
Optimal thresholds for delineating non-LBD from LBD and MSA
from PD were >2.0 for FDG PET (LBD vs. non-LBD: J= 0.68; PD vs.
MSA: J= 0.67) and >1.3 for MIBG scintigraphy (LBD vs. non-LBD: J=
0.44; PD vs. MSA: J= 0.40), leading to a comparable sensitivity of 94%
(85–100%) and 96% (75–100%) for FDG PET and 91% (47–100%) and
93% (46–100%) for MIBG scintigraphy, respectively. In contrast, the
specificity was notably higher for FDG PET (74% [53–95%] and 71%
[47–94%], respectively) than for MIBG scintigraphy (53% [32–95%]
and 47% [29–94%], respectively). Corresponding positive and
negative predictive values and positive and negative likelihood
ratios for the present patient population are listed in Table 2. These
also suggest superiority of FDG PET over MIBG scintigraphy (we
refrained from additional pairwise statistical comparisons given the
preceding comparisons of ROC analyses). Typical findings for both
modalities are shown in Fig. 3.
Using the aforementioned thresholds, five and two FDG PET
ratings were classified respectively as false-positive (i.e. imaging
diagnosis of non-LBD in case of clinical LBD) and false-negative
(i.e. imaging diagnosis of LBD in case of clinical non-LBD). In the
case of MIBG scintigraphy, there were nine false-positive and three
false-negative ratings. Of note, in four false-positive cases and one
false-negative case, the FDG PET and MIBG scintigraphy ratings
were congruent.
Finally, within the groups of patients with APS according to the
clinical follow-up diagnosis (n= 31), FDG PET ratings indicated
MSA (n= 26), PSP (n= 3), CBS (n= 1), or PD (n= 1). The FDG PET
ratings agreed with the clinical follow-up diagnosis in 87% of
cases (χ²= 12.37, p < 0.01) with the exceptions being n= 3 MSA
and n= 1 PSP by clinical diagnosis that were diagnosed with PD,
PSP and CBS, and MSA by FDG PET ratings, respectively.
DISCUSSION
The present study suggests that FDG PET provides higher
diagnostic accuracy than MIBG scintigraphy for the differentiation
between LBD and non-LBD as well as between PD and MSA using
the blinded follow-up diagnosis as reference. The differences
between both modalities did not reach statistical significance (p=
0.06 and p= 0.11, respectively), although FDG PET performed
significantly better than MIBG scintigraphy when considering the
individual ratings of the more experienced rater #1 (LBD vs. non-
LBD, p= 0.04; PD vs. MSA, p= 0.07).
These results extend prior studies by providing a within-subject
comparison of FDG PET and MIBG scintigraphy and match recent,
independent meta-analyses suggesting modest superiority of FDG
PET7,10. However, specificity of both modalities in the present
study were lower than previously described: for delineating non-
LBD from LBD, the calculated sensitivity of FDG PET (94%) was in
the upper range of the expected sensitivity (91%, 95%-CI: 72–98%)
based on a recent meta-analysis7, whereas the specificity (74%)
was at the lower limit of the expected range (91%; 95%-CI:
70–98%). MIBG scintigraphy discriminated both groups with 91%
sensitivity and 53% specificity, which is comparable sensitive
(83%; 95%-CI: 60–94%) but less specific (89%; 95%-CI: 82–95%)
compared to the values reported by a recent meta-analysis10 (note
that figures from this reference were adjusted to meet the present
definition of positive [non-LBD] and negative cases [LBD]). Aside
from the actual selection of the diagnostic cut-off values, the
difference between aforementioned studies and the present study
may also be related to the retrospective design of our study. We
included only patients investigated with both FDG PET and MIBG
scintigraphy for diagnostic purpose in clinical routine. In the
participating tertiary reference centers, patients fulfilling this
prerequisite are usually highly complex cases with clinically
Table 1. Demographic characteristics of patient groups.




Age at first imaging
(years)
Symptom duration at first
imaging (years)
Time of clinical observation
(years)
A LBD 6/13 61.3 ± 9.5 9.3 ± 6.8* 2.3 ± 2.5
Non-LBD 14/20 64.6 ± 9.3 3.9 ± 3.2* 1.4 ± 2.2
B PD 6/11 60.7 ± 9.5 9.6 ± 7.2** 2.5 ± 2.6
MSA 12/16 64.0 ± 9.1 3.7 ± 2.6** 1.6 ± 2.3
Data are presented as mean value ± SD. Diseases without Lewy bodies: MSA, n= 28; progressive supranuclear palsy, n= 3; drug-induced parkinsonism, n= 2;
normal pressure hydrocephalus, n= 1.
LBD Lewy body disease, non-LBD disease without Lewy bodies, PD Parkinson’s disease, MSA multiple system atrophy.
*p= 0.001, **p < 0.001, two-sample t test.
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inconclusive findings. Although the disease course revealed a
clear follow-up diagnosis in most of the patients, some clinical
uncertainty remained in some cases until the last contact.
Likewise, it can be expected that causes of clinical uncertainty
(e.g., comorbid conditions, very early or advanced disease stage)
may also translate into less typical imaging findings. Thus, both
clinical and imaging uncertainty may result in less optimal
estimates of the diagnostic accuracy in the present study
compared to earlier studies. The present results and their
statistical interpretation are obviously crucially dependent on
the actual sample size (e.g., see identical differences of ROC AUCs
for LBD vs. non-LBD [n= 53] and PD vs. MSA [n= 45], reaching a
statistical trend level only for the slightly larger sample, or the only
marginally higher AUC of rater #1 [0.83], implying a significant
difference, as apposed to the consensus read [0.82]). Thus,
confirmation of the present results by a larger patient sample is
advisable. Of note, the use of different scales (i.e. continuous for
MIBG scintigraphy and ordinal for FDG PET) may have introduced
a negative bias concerning the diagnostic performance of FDG
PET, since an ordinal scale with few steps may result in an
underestimation of the AUC11. By calculating the average score for
both raters, however, the consensus rating provided an 11-step
ordinal scale, which almost approximates a continuous scale so
that the effect is probably negligible.
Besides the more favorable diagnostic performance, an addi-
tional advantage of FDG PET over MIBG scintigraphy is the
possibility to further differentiate between the APS7. This also
applies to the present study, where 87% of patients with APS were




















































































Fig. 1 Boxplots for FDG PET and MIBG scintigraphy. a FDG PET and b MIBG scintigraphy in the differentiation of Lewy body diseases and
diseases without Lewy bodies. c FDG PET and d MIBG scintigraphy in the differentiation of multiple system atrophy and Parkinson’s disease.
Center line, median; box limits, upper and lower quartiles; whiskers, 1.5 × interquartile range; p values refer to Mann–Whitney U-test, d values
to Cohen’s effect size. non LBD disease without Lewy bodies, LBD Lewy body disease, H/M heart-to-mediastinum ratio, MSA multiple system
atrophy, PD Parkinson’s disease.
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correctly classified as either MSA or PSP by FDG PET. Although not
contemplated by the present study, FDG PET may also be used to
detect cortical involvement in PD and predict future cognitive
decline12–14. This may be of tremendous prognostic importance15
and of particular clinical relevance, e.g., in the context of deep
brain stimulation, where the risk of cognitive deterioration should
be estimated before surgery16,17.
MIBG scintigraphy has several handicaps in clinical practice.
First, its reliability is limited due to the fact that patients with early
PD (Hoehn & Yahr 1-2) show a normal MIBG uptake in more than
25% of cases18 and up to 30% of patients with MSA may show an
impaired cardiac innervation19. In combination with neuropatho-
logical findings (i.e., alpha-synuclein related pathology in thoracic
sympathetic ganglia in patients with advanced MSA20), the latter
suggests overlapping mechanisms of peripheral denervation in
both diseases and thus a conceptual limitation of cardiac MIBG
scintigraphy. Second, cardiac denervation is not specific for LBD
but may also be present in patients with congestive heart failure,
ischemic heart disease, or diabetic neuropathy21,22. These condi-
tions hamper proper differential diagnosis and need to be ruled
out before MIBG scintigraphy, which might require additional
diagnostic procedures and restricts the target population of MIBG
scintigraphy, especially in elderly patients. Lastly, several mechan-
isms of interference of various classes of drugs with MIBG exist
and can influence cardiac tracer uptake. Although standard
dopaminergic treatment is not critical, several common cardio-
vascular agents, antipsychotics, and antidepressants have inter-
actions and need to be discontinued according to their half-life up
to 4 weeks prior to imaging23,24. In our sample, a diligent review of
patient charts ruled out that patients had relevant comorbidities
or received any interfering medication at time point of imaging.
Therefore, we can exclude these confounders. However, if not
considered carefully, the diagnostic accuracy of MIBG scintigraphy
might be even lower than currently recorded.
Considering FDG PET, earlier studies indicated that its diagnostic
accuracy is not relevantly affected by disease-stage and common
medications7, while comorbidities with morphological brain altera-
tions (e.g., gross atrophy, ischemic lesions) may complicate image
interpretation. Furthermore, FDG PET might have one disadvantage
towards MIBG scintigraphy in certain clinical settings: If disease-
specific metabolic patterns are identified by visual reads and not
automated classification methods7, the diagnostic accuracy of FDG
PET may rely on the experience of the reader. Correct ROI placement
on planar MIBG images, in turn, is easier to learn and makes image
evaluation less susceptible to the reader’s experience than is the case
for FDG PET. This is also suggested by the present study, in which the
independent rating of the more experienced investigator indicated
statistically significant superiority of FDG PET, which was not the case
for the less experienced investigator. However, the actual difference
between both readers was small (see above), which we attribute to
the auxiliary use of easy-to-interpret voxel-based statistical analyses.
With the support of three-dimensional stereotactic surface projec-
tions or single-subject SPM analyses, non-expert investigators can
achieve a diagnostic accuracy, which is similar to the performance of
experts25,26.
The retrospective nature of the present study implies an inherent
risk of bias. We addressed this by creating clinical vignettes
containing comprehensive clinical data in line with current
diagnostic criteria. These were filled in by the same expert at every
center, which were then evaluated by two blinded movement
disorder specialists in consensus. However, having received both
imaging techniques, the patient populations probably entail a
selection bias towards complex cases, which probably leads to more
conservative estimates of the diagnostic accuracies of the enrolled
methods (see above). Of note, the order of both examinations was
roughly balanced which argues against a possible bias. Another
limitation related to the retrospective design is the time gap
between scans. However, the exclusion of six subjects with a time
gap >3 months did not reveal a relevant effect on the study outcome
(data not shown in detail). Another potential source of bias is the use
of different collimators at each study center, what we accounted for
by using a linear correction method27,28. However, separate ROC
analyses for each center are in agreement with the overall results
suggesting that the use of different collimators did not have a major
impact on the results (see Supplementary Table 2).
Given the limited accuracy of the clinical diagnosis of LBD and APS
as illustrated by clinicopathological studies29–33, the reliance on the
clinical diagnosis represents another limitation. We tried to minimize
the risk of incorrect clinical diagnosis by including all accessible
patient information into the vignettes. However, the observation that
MIBG: AUC = 0.69; p = 0.024
FDG: AUC = 0.82; p = p < 0.001















MIBG: AUC = 0.69; p = 0.035
FDG: AUC = 0.82; p = p < 0.001















Fig. 2 Receiver operating characteristic curves. a Differentiation of Lewy body disease from diseases without Lewy bodies and
b differentiation of Parkinson’s disease and multiple system atrophy. MIBG MIBG scintigraphy, FDG FDG positron emission tomography, AUC
Area under the receiver operating characteristic curve.
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a substantial fraction of incorrect FDG PET and MIBG scintigraphy
ratings occurred unanimously (in particular, see false-positive cases in
Fig. 1 with highly confident FDG PET ratings and high H/M ratios)
may suggest that actually the clinical diagnosis was false-negative in
these FDG PET and MIBG scintigraphy-positive cases. This underlines
the general need for future prospective studies including the post
mortem histopathological diagnose as reference in the field of
imaging in parkinsonian syndromes7.
Taken together, in the present study involving a clinically
challenging patient population, FDG PET and MIBG scintigraphy
correctly classified approximately four out of five and two out of
three patients, respectively. Albeit this notable difference did not
attain statistical difference, we consider this finding clinically
relevant and suggest that FDG PET, which also allows for
subgrouping of APS, should be preferred.
METHODS
Patients
The present study represents a retrospective analysis of imaging data from
two university hospitals. The patients came from three tertiary referral
centers specialized in movement disorders. We screened the records of the
Department of Nuclear Medicine, Medical Center - University of Freiburg
and the Department of Nuclear Medicine, University Hospital Würzburg
between 2012 and 2018 for patients who received both FDG PET and MIBG
scintigraphy. Patients who underwent both imaging techniques for the
differential diagnosis of LBD and APS, and had a clinical follow-up ≥1 year
were eligible for this study (inclusion criteria; in total n= 54; Freiburg n=
27; Würzburg n= 27). Incomplete clinical data, interfering medication at
the time of MIBG scintigraphy and/or corrupted image data served as
exclusion criteria. Forty patients (74.1%) completed both scans within one
week and forty-eight patients (88.9%) within three months. The mean time
between both scans was 10 weeks ±34 weeks.
The clinical follow-up diagnosis served as reference standard. To
standardize this process across all three referral sites, one movement
disorder specialist (N.S.) blinded to FDG PET and MIBG scintigraphy
reviewed all available information from the first to the last patient contact
of each subject (i.e., time of clinical observation). The information included
prior patient history and clinical follow-up (≥1 year), all physical and
neurological examinations, clinical charts (incl. past and present medica-
tions), tilt-table test, Schellong test, urodynamic study, and imaging results
other than FDG PET and MIBG scintigraphy (i.e. transcranial sonography,
MRI, CT, and dopamine transporter SPECT), and was incorporated into a
standardized clinical case vignette derived from the current diagnostic
criteria of LBD and APS3–6,34. In analogy to an earlier study35, we developed
the structure of the vignette for this study specifically, which contained
Table 2. Discriminative measures of FDG PET and MIBG scintigraphy.
Analysis Modality ROC AUC Sensitivity Specificity PPV NPV LR+ LR−
A MIBG 0.69 (0.53–0.85) 0.91 (0.47–1.00) 0.53 (0.32–0.95) 0.78 (0.71–0.94) 0.77 (0.47–1.00) 1.92 (1.26–3.53) 0.17 (0.00–0.45)
FDG 0.82 (0.68–0.97) 0.94 (0.82–1.00) 0.74 (0.53–0.95) 0.86 (0.78–0.96) 0.88 (0.70–1.00) 3.58 (1.99–14.06) 0.08 (0.00–0.22)
B MIBG 0.69 (0.52–0.86) 0.93 (0.46–1.00) 0.47 (0.29–0.94) 0.74 (0.69–0.95) 0.80 (0.48–1.00) 1.75 (1.17–3.10) 0.15 (0.04–0.45)
FDG 0.82 (0.67–0.98) 0.96 (0.75–1.00) 0.71 (0.47–0.94) 0.84 (0.76–0.96) 0.92 (0.68–1.00) 3.28 (1.72–8.44) 0.05 (0.00-0.18)
Values in parentheses give 95% confidence intervals.
A analysis for the differentiation of Lewy body diseases versus diseases without Lewy bodies, B analysis for the differentiation of Parkinson’s disease versus
multiple system atrophy, MIBGMIBG scintigraphy, FDG FDG positron emission tomography, ROC AUC area under the receiver operating characteristic curve, PPV






































Fig. 3 Typical FDG PET and MIBG scintigraphy findings in individual patients with Parkinson’s disease and multiple system atrophy. a
Spatially normalized transaxial FDG PET slices at the level of cerebellum, basal ganglia, and dorsal frontoparietal cortex. Datasets were
thresholded for optimal display. b Anterior view of planar MIBG scintigraphy. The patient with PD shows a typical relative hypermetabolism of
the bilateral putamen and no cardiac MIBG uptake. The MSA patient is characterized by hypometabolism of the putamen (particularly on the
left side), the bilateral cerebellum, and a preserved cardiac uptake on MIBG scintigraphy. PD Parkinson’s disease, MSA multiple system atrophy.
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sections with demographic information, symptomatology, diagnostic
findings, therapy, and disease course, covering all relevant information
before and after imaging procedures (see Supplementary Data 1 for the
template of the vignette). Of note, results of FDG PET and MIBG
scintigraphy, as well as the diagnosis of the treating neurologists were
not recorded. Two board-certified neurologists and movement disorder
specialists (W.H.J. and I.U.I.) independently evaluated the clinical vignettes
of all patients according to current diagnostic criteria3–6,34. The rating
contained two consecutive levels: first, raters classified each vignette as
indicative for LBD, APS, or other. Second, raters sub-classified patients with
LBD and APS as PD, PDD, or DLB and PSP, MSA, or CBS, respectively. After
independent assessment of all vignettes, both raters reached a consensus
follow-up diagnosis (i.e. the reference standard).
FDG PET
Patients were examined in medication-on state (if applicable) since the effect
of dopaminergic medication on FDG PET is considered negligible7. Scans
were obtained either on a Biograph mCT 64 (Siemens Medical Solutions,
Knoxville, TN; n= 27, mean ± SD injected dose, 204 ± 10 MBq FDG) or a
Philips Gemini TrueFlight 64 integrated PET/CT system (TF64, Philips,
Eindhoven, The Netherlands; n= 27, 214 ± 8 MBq FDG). PET emission data
were acquired 30min post-injection on the Biograph mCT64 and 50min
post-injection on the Philips Gemini TrueFlight in 3-dimensional mode for
10min in accordance with current procedural guidelines for FDG brain
imaging36. PET data were reconstructed iteratively and fully corrected for
randoms, scatters, and photon attenuation using a low-dose CT for
attenuation correction and vendor-specific reconstructions methods.
We performed FDG PET data analysis with an in-house pipeline written
in MATLAB (The MathWorks, Inc.) and employing statistical parametric
mapping routines (SPM12, Wellcome Department of Cognitive Neurology,
University College, London). We spatially normalized the scans to an FDG
PET template image in Montreal Neurological Institute (MNI) brain space,
followed by proportional scaling of voxel-wise FDG uptake to mean global
brain parenchyma FDG uptake. Two board-certified nuclear medicine
physicians (P.T.M. and C.L.), blinded to clinical information, then
independently rated FDG PET scans of all 54 patients by using 30
transaxial slices (4.5 mm thickness) covering the entire brain. Slices were
displayed in a standardized fashion (maximum adjusted for optimal
display, minimum set to 5% of maximum, monochrome “hot metal” color
scale). As supportive analyses, readers had access to three-dimensional
stereotactic surface projections (3D SSP; Neurostat software) displaying the
deviation of each individual’s regional cerebral FDG uptake from age-
matched healthy controls (color-coded Z score 0–7; decreases only)37 and
the results of single-subject SPM analyses showing significantly (p < 0.05,
k > 50 voxels, no correction for multiple comparisons) hyper- and
hypometabolic regions in individual scan compared to healthy controls
of comparable ages examined with identical scanners (Gemini TrueFlight:
21 females/14 males, age: 77.6 ± 5.9 years; Biograph mCT: 5 females/5
males, age: 61.9 ± 14.4 years)25. The raters interpreted FDG PET scans in
two consecutive levels9 based on previously published disease-specific
patterns of regional cerebral glucose metabolism7:
1. First level: readers classified each scan as indicative of LBD or APS
using a 6-step score (0/1/2: definite/probable/possible LBD; 3/4/5:
possible/probable/definite APS).
2. Second level: readers categorized APS-positive scans (scores 3–5 at
first level) as being indicative of MSA, PSP, or CBS.
After independent evaluation of all scans, the raters averaged the scores
(yielding an 11-step scale) and reached a consensus second-level
diagnosis.
MIBG scintigraphy
We reviewed patient charts to rule out medication possibly interfering with
MIBG scintigraphy23,38. MIBG studies were acquired on a dual-headed gamma
camera (E.CAM [Siemens Healthineers, Erlangen, Germany], n= 10) and two
dual-headed SPECT/CT systems (Symbia T2 [Siemens Healthineers, Erlangen,
Germany], n= 27; Brightview XCT [Philips Medical Systems Inc. Cleveland,
OH], n= 17). Systems were equipped with either a low-energy high resolution
collimator (LEHR; E.CAM and Brightview XCT; n= 27, 192 ± 27 MBq MIBG) or a
medium-energy low penetration collimator (MELP; Symbia T2; n= 27, 183 ± 7
MBq MIBG). Anterior and posterior planar images were obtained for 10min at
240min after injection. Two board-certified nuclear medicine physicians (C.L.
and J.B., blinded to clinical information) evaluated MIBG uptake semi-
quantitatively by calculating the delayed heart-to-mediastinum ratio (H/M)
using the planar anterior images. They independently defined region-of-
interests (ROI) of the heart and the mediastinum by manually adjusting a
circular ROI to the left ventricle and a rectangular ROI to the upper
mediastinum using PMOD Version 3.7 (PMOD Technologies Ltd., Zurich,
Switzerland). The H/M of each patient was calculated by dividing the mean
counts per pixel in the cardiac ROI by the mean counts per pixel in the
mediastinal ROI. We then linearly converted the H/M ratio of the patients who
had been investigated on the system with the MELP collimator (n= 27) into
H/M ratios for LEHR collimators27,28 and calculated the mean H/M ratio of
both raters for each patient.
Statistical analysis
We used the statistics software R 3.3.3 [http://www.R-project.org/] for
statistical analyses. Inter-rater agreement was evaluated with the intra-
class-correlation coefficient (ICC) and Cohen’s (weighted) kappa (κ) as
applicable (R package ‘psych’, version 1.8.12). Between-group differences
were assessed using two-sample t test, Mann-Whitney U-test, and Cohen’s
effect size d (R package ‘effsize’, version 0.7.4). Receiver operating
characteristic (ROC) analyses (R package ‘pROC’, version 1.10.0) were
employed to assess and compare the diagnostic performance of the two
methods by the area under the ROC curve (AUC). We defined diseases
other than LBD (non-LBD; i.e., APS in the vast majority of cases) and MSA,
respectively as positive cases for calculating sensitivity and specificity. We
selected the thresholds for interpreting FDG PET and MIBG scintigraphy in
order to maximize Youden’s J (J= sensitivity+specificity−1). The associa-
tion between the clinical follow-up diagnosis and FDG PET ratings was
assessed with Pearson’s χ² test in the subgroup of APS patients.
Ethical approval and patient consent
Cardiac MIBG scintigraphy and FDG PET scans were performed as part of
the clinical work-up. All patients gave written informed consent to the
diagnostic procedures. All procedures performed in humans were in
accordance with the principles of the Declaration of Helsinki and its later
amendments or comparable ethical standards. The retrospective analysis
was approved by the local institutional review boards of the University
Hospital Freiburg and the Julius-Maximilian-University Würzburg.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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